What does MARKRI-FARMA do?

MARKRI-FARMA is a pharmacy in Herent. Private Limited, started on 3 August 2009, 1 establishment.

What is the address of MARKRI-FARMA?

The registered office of MARKRI-FARMA is located at Stationsstraat 37, 3020 Herent.

Is MARKRI-FARMA still active?

Yes. According to the CBE (31 October 2026) MARKRI-FARMA is active, legal situation “Normale toestand”, started on 3 August 2009.

Is MARKRI-FARMA registered on Peppol?

Yes, MARKRI-FARMA is registered on the Peppol network with ID 0208:0817521047.

What is the enterprise number of MARKRI-FARMA?

The enterprise number of MARKRI-FARMA is BE0817521047.

When was MARKRI-FARMA founded?

MARKRI-FARMA was founded on 3 August 2009.

Who are the directors of MARKRI-FARMA?

According to the 2025 annual accounts, the directors of MARKRI-FARMA are: Kristel Peeters, Marijke Peeters.

Is MARKRI-FARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 August 2009; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did MARKRI-FARMA make in 2025?

MARKRI-FARMA posted a profit after taxes of € 161,353 in financial year 2025.

What is the revenue of MARKRI-FARMA?

As a small company, MARKRI-FARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 209,285.

MARKRI-FARMA (Private Limited) - Herent - BE0817521047

Dossier MARKRI-FARMA, printed on 31 October 2026 from databakkes.be/en/0817521047/markri-farma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 17 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

MARKRI-FARMA from Herent, company number BE0817521047, closed financial year 2025 with a result of € 161,353 after tax. For that financial year MARKRI-FARMA recorded a gross margin of € 209,285 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € 140,790 to € 161,353. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 26, 2025.

What it is worth Growing

€ 1.3 million

▲ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 161,353

▲ 15% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 56,665

▲ 31% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.3 million.

People and assets in 2025

Vehicles and equipment

€ 9,832

▼ 53% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.1 million

▲ 15% vs 2024

€ 150,003 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 5,600

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 6,278

▼ 70% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 267,896 Gross margin 2022: € 267,896 First fiscal year in the series	€ 219,561 Gross margin 2023: € 219,561 ▼ 18% vs 2022 (€ 267,896) Unfavourable step	€ 220,163 Gross margin 2024: € 220,163 Unchanged (€ 219,561) Favourable step	€ 209,285 Gross margin 2025: € 209,285 ▼ 5% vs 2024 (€ 220,163) Unfavourable step	▼ 5%
Profit after taxes	€ 253,196 Profit after taxes 2022: € 253,196 First fiscal year in the series	€ 156,819 Profit after taxes 2023: € 156,819 ▼ 38% vs 2022 (€ 253,196) Unfavourable step	€ 140,790 Profit after taxes 2024: € 140,790 ▼ 10% vs 2023 (€ 156,819) Unfavourable step	€ 161,353 Profit after taxes 2025: € 161,353 ▲ 15% vs 2024 (€ 140,790) Favourable step	▲ 15%
Equity	€ 1,271,182 Equity 2022: € 1,271,182 First fiscal year in the series	€ 1,428,001 Equity 2023: € 1,428,001 ▲ 12% vs 2022 (€ 1,271,182) Favourable step	€ 1,251,283 Equity 2024: € 1,251,283 ▼ 12% vs 2023 (€ 1,428,001) Unfavourable step	€ 1,277,636 Equity 2025: € 1,277,636 ▲ 2% vs 2024 (€ 1,251,283) Favourable step	▲ 2%
Total debts	€ 1,387,212 Total debts 2022: € 1,387,212 First fiscal year in the series	€ 1,205,306 Total debts 2023: € 1,205,306 ▼ 13% vs 2022 (€ 1,387,212) Favourable step	€ 1,377,109 Total debts 2024: € 1,377,109 ▲ 14% vs 2023 (€ 1,205,306) Unfavourable step	€ 1,322,489 Total debts 2025: € 1,322,489 ▼ 4% vs 2024 (€ 1,377,109) Favourable step	▼ 4%
Cash	€ 84,017 Cash 2022: € 84,017 First fiscal year in the series	€ 70,180 Cash 2023: € 70,180 ▼ 16% vs 2022 (€ 84,017) Unfavourable step	€ 43,240 Cash 2024: € 43,240 ▼ 38% vs 2023 (€ 70,180) Unfavourable step	€ 56,665 Cash 2025: € 56,665 ▲ 31% vs 2024 (€ 43,240) Favourable step	▲ 31%
Retained profit	€ 1,129,482 Retained profit 2022: € 1,129,482 First fiscal year in the series	€ 1,286,301 Retained profit 2023: € 1,286,301 ▲ 14% vs 2022 (€ 1,129,482) Favourable step	€ 1,109,583 Retained profit 2024: € 1,109,583 ▼ 14% vs 2023 (€ 1,286,301) Unfavourable step	€ 1,270,936 Retained profit 2025: € 1,270,936 ▲ 15% vs 2024 (€ 1,109,583) Favourable step	▲ 15%
Dividend	€ 585,431 Dividend 2022: € 585,431 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 585,431) Unchanged	€ 317,508 Dividend 2024: € 317,508 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 317,508) Unchanged	▼ 100%
Bank debt	€ 742,471 Bank debt 2022: € 742,471 First fiscal year in the series	€ 1,142,469 Bank debt 2023: € 1,142,469 ▲ 54% vs 2022 (€ 742,471) Unfavourable step	€ 992,466 Bank debt 2024: € 992,466 ▼ 13% vs 2023 (€ 1,142,469) Favourable step	€ 1,142,463 Bank debt 2025: € 1,142,463 ▲ 15% vs 2024 (€ 992,466) Unfavourable step	▲ 15%
Balance sheet total	€ 2,658,394 Balance sheet total 2022: € 2,658,394 First fiscal year in the series	€ 2,633,308 Balance sheet total 2023: € 2,633,308 ▼ 1% vs 2022 (€ 2,658,394) Unchanged	€ 2,628,393 Balance sheet total 2024: € 2,628,393 Unchanged (€ 2,633,308) Unchanged	€ 2,600,125 Balance sheet total 2025: € 2,600,125 ▼ 1% vs 2024 (€ 2,628,393) Unchanged	▼ 1%

Key figures of MARKRI-FARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to MARKRI-FARMA?

What happened at MARKRI-FARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 26, 2025 New annual accounts for financial year 2025: profit of € 161,353 (▲ 15% vs 2024). Source: NBB ↗
Aug 3, 2009 Start of the company according to the CBE. KBO
Jul 15, 2009 New establishment in Zemst. KBO
2009 Kristel Peeters became a director. NBB
2009 Marijke Peeters became a director. NBB

In short

From € 253,196 profit in 2022 to € 161,353 profit in 2025.

Paid € 227,443 in corporate taxes since 2022.

Best year ever: 2022, with € 253,196 profit.

Paid out € 902,939 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Kristel Peeters

Marijke Peeters

MARKRI-FARMA

Apotheek Veltem Pharma 100%

Behind MARKRI-FARMA are Kristel Peeters and Marijke Peeters. It owns 100% of Apotheek Veltem Pharma itself.

Directors

According to the 2025 annual accounts

Kristel Peeters

Director

since 2009

Marijke Peeters

Director

since 2009

Establishments

Establishment units

Physical locations of this company

Registered office

Stationsstraat 37

3020 Herent

2.180.525.950

Vredelaan 22

1982 Zemst

Active since 15 July 2009

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK VELTEM_PHARMA same network

€ 425,653 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0817.521.047

VAT number

BE 0817.521.047

Registered office

Stationsstraat 37, 3020 Herent

Names & denominations

MARKRI-FARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

3 August 2009

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Detailhandel in farmaceutische producten

Vervaardiging van geneesmiddelen

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Vervaardiging van andere organische chemische basisproducten

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

MARKRI-FARMA

Warning lights

Financials

What happened to MARKRI-FARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions